The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old
![]() |
Kim, Eun-Seog
(Departments of Radiation Oncology, Soonchunhyang University School of Medicine)
Choi, Doo-Ho (Departments of Radiation Oncology, Soonchunhyang University School of Medicine) Jin, So-Young (Departments of Pathology, Soonchunhyang University School of Medicine) Lee, Dong-Wha (Departments of Pathology, Soonchunhyang University School of Medicine) Park, Hee-Sook (Departments of Medicine, Soonchunhyang University School of Medicine) Lee, Min-Hyuk (Departments of General Surgery, Soonchunhyang University School of Medicine) Won, Jong-Ho (Departments of Medicine, Soonchunhyang University School of Medicine) Kim, Yong-Ho (Departments of Radiation Oncology, Soonchunhyang University School of Medicine) Lee, Kyu-Taek (Departments of Medicine, Soonchunhyang University School of Medicine) Kim, Sung-Yong (Departments of General Surgery, Soonchunhyang University School of Medicine) |
1 | Ministry of Health and Welfare. Annual report of the central cancer registry in Korea, Seoul. Ministry of Health and welfare 2001 |
2 | Jung MS, Yoon HS, Park EH, Son BH, Ahn SE. Clinical characteristics and prognosis of breast cancer in very young Korean women. Global Breast Conference 2007 Abstract #GBCC01-032 |
3 | Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-1717 DOI ScienceOn |
4 | Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2007;24 (Republication ahead of print) |
5 | Han SW, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a high aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and Cathepsin D protein. J Surg Oncol 1997;65:22-27 DOI ScienceOn |
6 | Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635 PUBMED |
7 | Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative analysis of breast cancer tissue microarrays shows high COX-2 expression is associated with poor outcome. Cancer Invest 2007;25:19-26 DOI ScienceOn |
8 | Park BW, Kim SI, Kim EK, Yang WI, Lee KS. Impact of patients age on the outcome of primary breast cancer. J Surg Oncol 2002;80:12-18 DOI ScienceOn |
9 | Choi DH, Shin DB, Lee MH, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587-1595 DOI ScienceOn |
10 | Al-joudi FS, Iskandar ZA, Hasnan J, et al. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Med J 2007;48:607-614 PUBMED |
11 | Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med 2005;353:1659-1672 DOI ScienceOn |
12 | Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003;9:4914-4925 PUBMED |
13 | Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in situ and invasive breast cancer related to COX-2 expression and DCIS recurrence. Br J Cancer 2006;30:253-258 |
14 | Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-134 PUBMED |
15 | Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256 DOI PUBMED ScienceOn |
16 | Half A, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-1681 PUBMED |
17 | Spizzo G, GastlG, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-578 DOI ScienceOn |
18 | Choi DH, Kim ES, Kim YH, et al. Prognostic significance of COX-2 expression in young Korean patients with invasive breast carcinoma. Suppl. J Clin Oncol 2005;23:829 DOI |
19 | Son BH, Kwak BS, Kim JK, et al. Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg 2006;141:155-160 DOI ScienceOn |
20 | Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7:24-31 PUBMED |
21 | Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptorpositive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-1291 DOI PUBMED |
22 | Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921 DOI ScienceOn |
23 | Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54 DOI ScienceOn |
24 | Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under 35. Cancer 2003;97:134-147 DOI ScienceOn |
25 | Choi DH, Lee MH, Ahn YH, et al. Characteristics of HER-2/neu Oncogene in Korean women with early-onset breast cancer by immunohistochemistry and fluorescence in situ hybridization. J Breast Cancer 2003;6:255-262 |
26 | Ahn JH, Kim SB, Ahn SH, et al. Clinical value of cyclooxygenase expression in human breast carcinoma. Cancer Res Treat 2004;36:192-198 DOI ScienceOn |
27 | Kennedy SM, Driscoll LO, Purcell R, et al. Prognostic importance of survivin in breast cancer. Brit J Cancer 2003;88:1077-1083 DOI ScienceOn |
28 | Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease free survival in women with operable breast cancer. BMC Cancer 2004;17:82 |
29 | Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast cancer have a poor prognosis than older women. Cancer 1996;77:97-103 DOI ScienceOn |
30 | Harris L, Herbert F, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312 DOI ScienceOn |
31 | Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu positive breast cancer. J Biol Chem 2002;277:18649-18657 DOI ScienceOn |
32 | Park KM, Kim JY, Lim SJ. Comparing fluorescence in situ hybridization and immunohistochemistry to direct HER-2/neu status in breast carcinoma. Korean J Pathol 2002;36:243-248 |
33 | O'Driscoll L, Linehan R, Kennedy S, et al. Lack of prognostic significance of survivin, survivin deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201:225-236 DOI ScienceOn |
34 | Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182 DOI |
35 | Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 DOI ScienceOn |
36 | Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-135 |
37 | Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res TR 2000;63:213-223 DOI ScienceOn |
38 | Choi DH, Kim S, Rimm DL, Carter D, Haffty BG. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J 2005;11:404-411 DOI |
39 | Hunter CP. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer 2000;88:1193-1202 DOI ScienceOn |
40 | Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chemistry 2004;50:1986-1993 DOI ScienceOn |
41 | Singer-Ranger G, Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer and implications of COX-2 inhibition. Eur J Surg Oncol 2002;28:729-737 DOI ScienceOn |
![]() |